Keyphrases
Radiotherapy
100%
Cancer Patients
100%
Esophageal Cancer
100%
Volumetric Modulated Arc Therapy
100%
Dosimetric Parameters
100%
Chemoradiation
40%
Lung
30%
Cisplatin
20%
Postoperative Complications
10%
No Significant Difference
10%
Clinically Significant
10%
Histogram
10%
Patient Cohort
10%
Gross Total Resection
10%
Dmax
10%
Chemotherapy
10%
Treatment Group
10%
Neoadjuvant Chemoradiotherapy (nCRT)
10%
5-fluorouracil (5-FU)
10%
Oxaliplatin
10%
Progression-free Survival
10%
Cetuximab
10%
Reduced Toxicity
10%
Baseline Characteristics
10%
Total Dose
10%
Organs at Risk
10%
Anastomotic Insufficiency
10%
Planning Target Volume
10%
Dosimetric Differences
10%
Postoperative Pneumonia
10%
Medicine and Dentistry
Radiation Therapy
100%
Esophageal Cancer
100%
Volumetric Modulated Arc Therapy
100%
Chemoradiotherapy
50%
Cisplatin
20%
Postoperative Complication
10%
Surgical Anastomosis
10%
Infusion
10%
Oxaliplatin
10%
Group Therapy
10%
Progression Free Survival
10%
Surgery
10%
Cetuximab
10%
Pharmacology, Toxicology and Pharmaceutical Science
Chemoradiation Therapy
100%
Esophagus Cancer
100%
Cisplatin
40%
Chemotherapy
20%
Progression Free Survival
20%
Postoperative Complication
20%
Oxaliplatin
20%
Cetuximab
20%
Immunology and Microbiology
Progression Free Survival
100%
Cetuximab
100%